(Reuters) – Bristol-Myers Squibb Co said the U.S. Food and Drug Administration declined to approve its immuno-oncology drug, Opdivo, for its expanded use to treat an additional type of advanced skin cancer.
FDA declines expanded approval for Bristol-Myers’ Opdivo drug
November 28, 2015By
